• Bluebird Bio, TC BioPharm Partner to Develop Gamma Delta CAR T-cell Therapy Candidates
  • Genentech Combo Delays Kidney Cancer Progression, Phase 3 Trial Shows
  • In Phase 2 Trial, Orencia Prevented Graft-Versus-Host Disease After Stem Cell Transplant
  • City of Hope CAR T-cell Therapy Shows Promise in Hard-to-Treat Blood Cancers
  • Health Canada OKs Start of Enrollment in Phase 2 DPX-Survivac Trial for DLBCL
  • More Mutations in Melanoma Cells Predict Better Responses to Immunotherapy
  • $5M CIRM Grant Awarded to Continue Development of CD47 Antibody to Treat AML and MDS
  • Bavencio Fails to Increase Survival of Advanced Gastric Cancer Patients in Phase 3 Trial
  • Phase 3 Opdivo Trial Ends Early After Showing Better Survival Rates than Docetaxel in NSCLC
  • Cerenis May Develop HDL Cholesterol as Tumor Visualization Tool for Targeted Cancer Therapy
  • EMA to Review Opdivo-Yervoy Combo as Treatment for Renal Cancer
  • IMO-2125, Yervoy Combo is on Fast Track for Treating Refractory Metastatic Melanoma